Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed Announces $140 Million Deal to Out-license Autoimmune Therapy to CSPC

publication date: Oct 12, 2022

Harbour BioMed out-licensed Greater China rights for an autoimmune therapy to CSPC NBP Pharma in a deal worth up to $140 million, including $21 million upfront, plus royalties. NBP will be responsible for China clinical development, commercialization and manufacturing of batoclimab. The candidate is an anti-FcRn monoclonal antibody that accelerates the degradation of autoantibodies to treat pathogenic IgG-mediated autoimmune diseases. In 2017, Harbour acquired China rights to batoclimab in a two candidate deal from Korea’s HanAll Biopharma for $81 million. Harbour has started a China Phase III trial for batoclimab in myasthenia gravis patients. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital